Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Presented By Raymond Huang at 2014 ASCO Annual Meeting

Hazard Ratio 0.62 ( ) P =.024 Larynx and Hypopharynx Overall Survival 166 Patients.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Colorectal cancer intrinsic subtypes are associated with prognosis, chemotherapy response, deficient mismatch repair and epithelial to mesenchymal transition.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Presented By Christina Tsien at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.

XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

Presented By Michael Overman at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Preliminary data of Non- Small Cell Lung Cancer gene expression pilot study Tõnu Vooder, Kristjan Välk, Andres Metspalu Genoa 2005.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

A cura di Filippo de Marinis

Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.

Immunoscore Prognostic in Colon Cancer

Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Securing the cure in resectable lung cancer

Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Counseling Patients About Germline BRCA Mutations

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Supplementary Figure 2 Shiota et al.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Volume 152, Issue 1, Pages (January 2019)

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Patient stratification using survival risk prediction and BCLC staging

Presentation transcript:

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Disclosure Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 3 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11 PFS and OS Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11 PFS and OS High risk group suboptimal stage III and stage IV Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Molecular Classification of HGS Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 8 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 9 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 10 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 12 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Overall (n=359) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort High risk for progression (n=119) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Proliferative Subtype (n=96) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Mesenchymal Subtype (n=68) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Differentiated Subtype (n=73) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Immunoreactive Subtype (n=122) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 19 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Proliferative Subtype HGS (n=63) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Mesenchymal Subtype HGS (n=43) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Conclusion Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Acknowledgements Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting